Prescription Drug Pricing in America – a 3-Part Update, From the Over- the-Counter OPill and “Half-Price” Ozempic to Most-Favored-Nation Rx (Part 3)
Welcome to Part 2 of 3 in my consideration of Prescription Drug Pricing in America. You can catch up with yesterday’s Part 1 post here, and Part 2 here. The macro-context for these 3 posts are the forecasts for health care spending for the coming year. Health care cost increases forecasted for 2026 will, in significant part, be driven by prescription drug trend. This graphic from this week’s release of the Business Group on Health’s employer survey on healthcare cost growth to 2026 illustrates a key finding that’s echoed in other similar studies recently released and covered here in Health Populi.
Prescription Drug Pricing in America – a 3-Part Update, From the Over- the-Counter OPill and “Half-Price” Ozempic to Most-Favored-Nation Rx (Part 2)
“Big Pharma has a new vision for selling drugs. It’s going to the mattresses,” writes Josh Nathan-Kazis in MSN earlier this week. That is, going direct-to-consumer (DTC) the way the mattress industry has done in the past decade, cutting out brick-and-mortar sleep shops at retail. In the case of “Make(ing” like a mattress company,” Josh explains, the pharma manufacturers “sell shots and pills straight to the consumer.” In this case, that’s cutting out the pharmacy benefits managers and other intermediaries that have taken dollars in the transactions of drug benefit claims which have added costs to payers (health plan sponsors
Prescription Drug Pricing in America – a 3-Part Update, From the Over- the-Counter OPill and “Half-Price” Ozempic to Most-Favored-Nation Rx (Part 1)
Health care costs will increase, overall, as much as 10% in 2026, the consensus of several health benefit analysts inform us. And, “workers to bear brunt of health cost increases in 2026,” reads today’s Axios headline on the topic, weaving together several studies from the Business Group on Health, Mercer, and the International Foundation of Employee Benefit Plans. A kay cost-contributor cited in all of these health cost forecasts is the prescription drug line item: specialty drug prices, and specifically the costs of GLP-1 medicines and cancer therapies. One strategy gaining fast-traction on both the
How BioPharma Can Improve Consumers’ Experience and Health
Patients as health consumers now know what “good” looks like in their digital experiences. People have tasted the convenience and respect they feel from well-designed, streamlined omnichannel retail experiences, and they now expect this from health care — specifically supported by the pharmaceutical companies who manufacture the medicines they use in managing chronic conditions, we learn in ixlayer ixInsights 2025: Pharma’s Role in Improving the Health Experience from ixlayer and Ipaos. The patient-focused report gets specific about people dealing with asthma, COPD, Type 2 diabetes, heart disease, psoriasis, and atopic dermatitis with a lens on
How Disrupting the Generic ED Meds Sales Model Marries to Our Digital Coexistences – Mark Cuban at the Shelly Palmer Innovation Series Breakfast #CES2025
What was Mark Cuban doing “gate-crashing” Shelly Palmer’s Innovation Breakfast? My worlds of content and health care collided in a serendipitous way this morning when, at the conclusion of my annual beloved experience attending and learning at the Shelly Palmer Innovation Series breakfast which focuses on content, media, entertainment, and now AI mashing up everywhere, all at once, Mark Cuban appeared as a late-breaking guest in fireside chat with Shelly. Here’s my photo to prove it, circa 903 am this morning. Before even chatting about AI, X, and his
I'm once again pretty gobsmackingly happy to have been named a judge for the 2026 CES Innovation Awards, focusing on digital health, longevity, and fitness. Preceding every year's global conference, CES receives hundreds of applications from innovators around the world building tech-based solutions to big challenges. So glad to be part of this annual initiative to see what global health-tech pioneers are cooking up to address and scale the health and well-being of fellow health citizens, globally.
You can see the results of the Digital Health Awardees here on the #CES2026 website.
Stay tuned to Health Populi in early January as I'll be attending Media Days and meeting with innovators in digital health, longevity, and the home-for-health during CES 2026 in Las Vegas. I'll be at the conference for an entire week meeting with clients and exhibitors at the biggest-meeting-of-the-year on consumer-facing technology. I'll be reporting daily from Vegas here in the blog, sharing with you insights about the latest breakthroughs, products, and services that enable people to manage health, well-being, and medical issues in their own hands and homes.
Jane collaborated on Robin Strongin's Health Dame webcast to discuss Halle Tecco's new book, Massively Better Healthcare, due out in early 2026. We brainstormed with Maven Founder Kate Ryder and the company's Chief Medical Officer Dr. Neel Shah about the state of U.S. healthcare and solutions not just to tweak at the margins but to "massively" improve health care delivery, financing, outcomes, and equity in America. It was a delightful, enlightening conversation -- I hope you'll check it out.